Cargando…

Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic

Loss to follow-up (LF), which refers to patients who started care but voluntary stopped it, is a problem for patients with chronic disease. We aimed to estimate the rate of LF among patients seropositive for hepatitis C virus (HCV) and identify possible demographic and lifestyle risk factors associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendes, L.C., Ralla, S.M., Vigani, A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007075/
https://www.ncbi.nlm.nih.gov/pubmed/27580006
http://dx.doi.org/10.1590/1414-431X20165455
_version_ 1782451163025637376
author Mendes, L.C.
Ralla, S.M.
Vigani, A.G.
author_facet Mendes, L.C.
Ralla, S.M.
Vigani, A.G.
author_sort Mendes, L.C.
collection PubMed
description Loss to follow-up (LF), which refers to patients who started care but voluntary stopped it, is a problem for patients with chronic disease. We aimed to estimate the rate of LF among patients seropositive for hepatitis C virus (HCV) and identify possible demographic and lifestyle risk factors associated with LF. From January 2009 through December 2012, 1010 anti-HCV-positive patients were included in the study. Among participants, 223 (22.1%) met the case definition for LF (more than 1-year elapsed since the last clinical appointment). Among 787 patients who remained in follow-up, 372 (47.2%) were discharged after undetectable HCV RNA, 88 (11.1%) were transferred (and remained on regular follow-up at the destination), and 25 (3.1%) died. According to univariate analysis, male gender, absence of a life partner, black race, psychiatric illness, previous alcohol abuse, previous or current recreational drug use, and previous or current smoking were significantly associated with LF. In multivariate analysis, absence of a life partner (adjusted odds ratio (AOR)=1.44; 95% confidence interval (95%CI)=1.03–2.02), black race (AOR=1.81, 95%CI=1.12–2.89), psychiatric illness (AOR=1.77, 95%CI=1.14–2.73), and the presence of at least one lifestyle risk factor (pertaining to substance abuse) (AOR=1.95, 95%CI=1.29–2.94) were independently associated with LF. Our study provides an estimate of the incidence of LF among anti-HCV-positive patients and identifies risk factors associated with this outcome. In addition, these results can help clinicians recognize patients at risk for LF, who require additional support for the continuity of care.
format Online
Article
Text
id pubmed-5007075
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Associação Brasileira de Divulgação Científica
record_format MEDLINE/PubMed
spelling pubmed-50070752016-09-13 Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic Mendes, L.C. Ralla, S.M. Vigani, A.G. Braz J Med Biol Res Clinical Investigation Loss to follow-up (LF), which refers to patients who started care but voluntary stopped it, is a problem for patients with chronic disease. We aimed to estimate the rate of LF among patients seropositive for hepatitis C virus (HCV) and identify possible demographic and lifestyle risk factors associated with LF. From January 2009 through December 2012, 1010 anti-HCV-positive patients were included in the study. Among participants, 223 (22.1%) met the case definition for LF (more than 1-year elapsed since the last clinical appointment). Among 787 patients who remained in follow-up, 372 (47.2%) were discharged after undetectable HCV RNA, 88 (11.1%) were transferred (and remained on regular follow-up at the destination), and 25 (3.1%) died. According to univariate analysis, male gender, absence of a life partner, black race, psychiatric illness, previous alcohol abuse, previous or current recreational drug use, and previous or current smoking were significantly associated with LF. In multivariate analysis, absence of a life partner (adjusted odds ratio (AOR)=1.44; 95% confidence interval (95%CI)=1.03–2.02), black race (AOR=1.81, 95%CI=1.12–2.89), psychiatric illness (AOR=1.77, 95%CI=1.14–2.73), and the presence of at least one lifestyle risk factor (pertaining to substance abuse) (AOR=1.95, 95%CI=1.29–2.94) were independently associated with LF. Our study provides an estimate of the incidence of LF among anti-HCV-positive patients and identifies risk factors associated with this outcome. In addition, these results can help clinicians recognize patients at risk for LF, who require additional support for the continuity of care. Associação Brasileira de Divulgação Científica 2016-08-25 /pmc/articles/PMC5007075/ /pubmed/27580006 http://dx.doi.org/10.1590/1414-431X20165455 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Clinical Investigation
Mendes, L.C.
Ralla, S.M.
Vigani, A.G.
Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic
title Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic
title_full Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic
title_fullStr Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic
title_full_unstemmed Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic
title_short Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic
title_sort loss to follow-up in anti-hcv-positive patients in a brazilian regional outpatient clinic
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007075/
https://www.ncbi.nlm.nih.gov/pubmed/27580006
http://dx.doi.org/10.1590/1414-431X20165455
work_keys_str_mv AT mendeslc losstofollowupinantihcvpositivepatientsinabrazilianregionaloutpatientclinic
AT rallasm losstofollowupinantihcvpositivepatientsinabrazilianregionaloutpatientclinic
AT viganiag losstofollowupinantihcvpositivepatientsinabrazilianregionaloutpatientclinic